Editorial: The multimillion-dollar cure
by The Times Editorial Board, Los Angeles Times
May 28, 2019
4 minutes
Gilead Sciences, a California biopharmaceutical company, scored a major breakthrough in 2013 when the Food and Drug Administration approved Sovaldi, a pill that could cure hepatitis C when combined with another antiviral medication. And then Gilead delivered another breakthrough, albeit not a good one: It priced Sovaldi at $1,000 per pill, or $84,000 to $168,000 per course of treatment. The pricing stunned patients, insurers and state governments, which were suddenly exposed to billions of dollars in potential prescription costs.
But as it turns out, Sovaldi was just a milepost on the way to the six- and seven-figure prices that a new generation of specialty drugs
You’re reading a preview, subscribe to read more.
Start your free 30 days